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We welcome the interest of Rutgers and colleagues [1] in 
providing additional information on the mode of action 
of autologous conditioned serum (ACS). Studies such as 
the one they published in a recent issue of Arthritis 
Research & Th  erapy are important because the Orthokine 
ACS treatment (Orthogen, Düsseldorf, Germany) has 
been shown to be safe and eﬀ   ective in a number of 
clinical studies and is used widely in Europe. Randomized 
controlled trials have conﬁ   rmed the eﬃ   cacy  of  this 
treatment in osteoarthritis of the knee and lumbar 
radiculopathy. Additional human studies show promise 
in treating muscle injury and tunnel widening after 
anterior cruciate ligament (ACL) reconstruction. All 
clinical and preclinical studies conﬁ  rm an excellent risk-
to-beneﬁ  t ratio. We would like to oﬀ  er some comments 
concerning the paper of Rutgers and colleagues.
Th  e method of producing ACS has been carefully 
optimized to enrich for anti-inﬂ  ammatory cytokines, such 
as interleukin (IL)-1Ra, IL-10, and IL-13, while keeping 
low the concentration of inﬂ  ammatory cyto  kines, such as 
IL-1β and tumor necrosis factor-alpha (TNF-α). Th  e  ACS 
preparation of Rutgers and colleagues had increased con-
cen  trations of IL-1β and TNF-α, and this raises questions 
about the composition of the product that was tested.
Nevertheless, despite the elevated concentrations of 
these two cytokines, there was no adverse eﬀ  ect of ACS on 
proteoglycan turnover in the cartilage explant cultures. 
Th   is suggests that anti-inﬂ   ammatory and possibly 
chondro  protective ingredients within ACS pre  dominate. 
Further studies using additional controls and autologous 
instead of heterologous serum would be interesting.
Th  e third component of the study by Rutgers and 
colleagues measured cytokine levels in synovial ﬂ  uids 
before and after treatment with ACS. No changes were 
found, but it should be noted that Orthokine should be 
used only when knee eﬀ  usion has been removed eﬀ  ec-
tively. Th  e described possible aspiration of synovial ﬂ  uid 
after treatment with ACS raises questions about the 
selection of these patients or the composition of the 
injected ACS. In this regard, it is worth noting that another 
study [2,3] involving the injection of Orthokine ACS into 
knees after ACL plasty showed evidence of reduced IL-1β 
content in synovial ﬂ  uid.  Th  is reduction corresponded 
with im  proved pain and function and with reduced tunnel 
widening. Clearly, the mechanisms through which ACS 
brings about clinical improvement are incompletely under-
stood and should be the subject of additional research.
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